[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 159,280
  • Shares Outstanding, K 116,263
  • Annual Sales, $ 6,650 K
  • Annual Income, $ -136,320 K
  • EBIT $ -148 M
  • EBITDA $ -138 M
  • 60-Month Beta 2.23
  • Price/Sales 23.62
  • Price/Cash Flow N/A
  • Price/Book 0.77

Options Overview Details

View History
  • Implied Volatility 171.11% (-4.93%)
  • Historical Volatility 60.03%
  • IV Percentile 23%
  • IV Rank 7.62%
  • IV High 1,257.44% on 11/18/25
  • IV Low 81.57% on 06/04/25
  • Expected Move (DTE 22) 0.3910 (28.54%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 156
  • Volume Avg (30-Day) 154
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 7,919
  • Open Int (30-Day) 7,206
  • Expected Range 0.9790 to 1.7610

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 5
  • High Estimate $-0.27
  • Low Estimate $-0.31
  • Prior Year $-0.32
  • Growth Rate Est. (year over year) +9.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +26.36%
on 03/30/26
1.4500 -4.14%
on 04/13/26
+0.2400 (+20.87%)
since 03/23/26
3-Month
1.0400 +33.65%
on 03/19/26
1.6950 -17.99%
on 02/25/26
+0.1800 (+14.88%)
since 01/23/26
52-Week
0.9100 +52.75%
on 08/11/25
1.9399 -28.35%
on 10/27/25
+0.0600 (+4.51%)
since 04/23/25

Most Recent Stories

More News
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the...

SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.3900 (+1.46%)
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.3900 (+1.46%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.3900 (+1.46%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.3900 (+1.46%)
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.3900 (+1.46%)
Fate Therapeutics: Q4 Earnings Snapshot

Fate Therapeutics: Q4 Earnings Snapshot

FATE : 1.3900 (+1.46%)
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis...

FATE : 1.3900 (+1.46%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.3900 (+1.46%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.3900 (+1.46%)
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated...

FATE : 1.3900 (+1.46%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 1.4317
2nd Resistance Point 1.4153
1st Resistance Point 1.3927
Last Price 1.3900
1st Support Level 1.3537
2nd Support Level 1.3373
3rd Support Level 1.3147

See More

52-Week High 1.9399
Fibonacci 61.8% 1.5465
Fibonacci 50% 1.4250
Last Price 1.3900
Fibonacci 38.2% 1.3034
52-Week Low 0.9100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.